Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study
- 425 Downloads
The aim of this retrospective study was to evaluate the presence of risk factors for a type 1 gastric neuroendocrine neoplasia in a large cohort of patients with chronic atrophic gastritis. The study design consisted of an Italian multicentre, retrospective analysis. The study included all consecutive patients with chronic atrophic gastritis with or without type 1 gastric neuroendocrine neoplasias followed at the participating centres. Two hundred and twenty-nine patients with chronic atrophic gastritis were enroled at the participating centres. A total of 207 patients (154 female, 53 males, median age: 56.0 years) were included in the final analysis. One hundred and twenty-six patients had chronic atrophic gastritis without a gastric neuroendocrine neoplasia and 81 had a chronic atrophic gastritis with type 1 gastric neuroendocrine neoplasia. The median Chromogranin A level, evaluated in 141 patients, was 52.0 U/L. At upper gastrointestinal endoscopy, atrophy of the gastric mucosa was mild/moderate in 137 patients and severe in 68. Intestinal metaplasia of the corpus was present in 168 patients. At histological examination, 81 patients had a gastric neuroendocrine neoplasia (42 patients had a NET G1 and 33 a NET G2). The median Ki67 index was 2.0 %. At univariate and multivariate analysis, the risk factors for a gastric neuroendocrine neoplasia were: male gender, chromogranin A greater than 61 U/L, presence of intestinal metaplasia and age equal to or greater than 59 years. Chromogranin A greater than 61 U/L, the presence of intestinal metaplasia and male gender were independent risk factors for a type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis.
KeywordsNeuroendocrine tumours Chronic atrophic gastritis Gastric carcinoid Gastrin Chromogranin A
All authors approved the final version of the article, including the authorship list.
Compliance with ethical standards
Conflict of interest
Dr. Antongiulio Faggiano has received research grants from NOVARTIS Farma s.p.a. and IPSEN PHARMA. The other authors declare that they have no conflict of interest.
- 1.M. Rugge, P. Correa, M.F. Dixon, R. Fiocca, T. Hattori, J. Lechago, G. Leandro, A.B. Price, P. Sipponen, E. Solcia, H. Watanabe, R.M. Genta, Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment. Pharmacol. Ther. 16, 1249–1259 (2002)CrossRefPubMedGoogle Scholar
- 7.G. Rindi, C. Azzoni, S. La Rosa, C. Klersy, D. Paolotti, S. Rappel, M. Stolte, C. Capella, C. Bordi, E. Solcia, ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 116, 532–542 (1999)CrossRefPubMedGoogle Scholar
- 10.F.T. Bosman, F. Carneiro, R.H. Hruban, N.D. Theise. WHO Classification of Tumors of the Digestive System. 4th edn. IARC, Lyon, (2010)Google Scholar
- 11.G. Rindi, G. Kloppel, H. Alhman, M. Caplin, A. Couvelard, W.W. de Herder, B. Erikssson, A. Falchetti, M. Falconi, P. Komminoth, M. Korner, J.M. Lopes, A.M. McNicol, O. Nilsson, A. Perren, A. Scarpa, J.Y. Scoazec, B. Wiedenmann, TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 449, 395–401 (2006)CrossRefPubMedPubMedCentralGoogle Scholar
- 16.M. Peracchi, C. Gebbia, G. Basilisco, M. Quatrini, C. Tarantino, C. Vescarelli, S. Massironi, D. Conte, : Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. Eur. J. Endocrinol. 152, 443–448 (2005)CrossRefPubMedGoogle Scholar
- 19.H. Ohata, S. Kitauchi, N. Yoshimura, K. Mugitani, M. Iwane, H. Nakamura, A. Yoshikawa, K. Yanaoka, K. Arii, H. Tamai, Y. Shimizu, T. Takeshita, O. Mohara, M. Ichinose, Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int. J. Cancer 109, 138–143 (2004)CrossRefPubMedGoogle Scholar
- 21.S. Shichijo, Y. Hirata, K. Sakitani, S. Yamamoto, T. Serizawa, R. Niikura, H. Watabe, S. Yoshida, A. Yamada, Y. Yamaji, T. Ushiku, M. Fukayama, K. Koike, Distribution of intestinal metaplasia as a predictor of gastric cancer development. J. Gastroenterol. Hepatol 30, 1260–1264 (2015)CrossRefPubMedGoogle Scholar
- 25.A. Vanoli, S. La Rosa, O. Luinetti, C. Klersy, R. Manca, C. Alvisi, S. Rossi, E. Trespi, A. Zangrandi, F. Sessa, C. Capella, E. Solcia, Histologic changes in type A chronic atrophic gastritis indicating increased risk of neuroendocrine tumor development: the predictive role of dysplastic and severely hyperplastic enterochromaffin-like cell lesions. Hum. Pathol 44, 1827–1837 (2013)CrossRefPubMedGoogle Scholar